For the Inventor, By the Inventor

Enter assignee name

Dainippon Pharmaceutical Company, Limited

USPTO Granted Patents = 129

Trademarks = 2

Forward Citations = 1,445

Loading Chart...

Loading Chart...

225 inventors (with patents filed for the assignee):

Hitoshi Uno (20 out of 20 patents)

Jun-ichi Matsumoto (15 out of 15 patents)

Shinichi Nakamura (13 out of 13 patents)

4. Kiyoshi Furukawa (13 out of 13 patents)

5. Hideo Nakamura (11 out of 11 patents)

6. Masanao Shimizu (11 out of 11 patents)

7. Yoshiyuki Takase (11 out of 11 patents)

8. Shiro Kato (10 out of 11 patents)

9. Makoto Oka (10 out of 10 patents)

10. Katsuhiko Hino (9 out of 9 patents)

11. Toshiya Morie (8 out of 8 patents)

12. Kazunori Ohno (8 out of 8 patents)

13. Naoyuki Yoshida (8 out of 8 patents)

14. Tatsuya Kon (8 out of 8 patents)

15. Haruki Nishimura (8 out of 8 patents)

Core Competencies:

Pharmaceutical Compositions

Neurodegenerative Diseases

Heterocyclic Compounds

Elastase Inhibitors

Pyridine Derivatives

Chymase Inhibitors

Drug Delivery Systems

Amino Acid Derivatives

Anti-Tumor Agents

Polypeptides

Microbial Infection Treatments

129 patents: Sort by Forward Citations

1. 7514452 - 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same (2009-04-07),

2. 7176199 - Aryl-substituted alicyclic compound and medical composition comprising the same (2007-02-13),

3. 7115412 - Process for the preparation of optically active 7-substituted-3-(2-aminopropyl)indole derivatives and intermediates therefor (2006-10-03),

4. 7108987 - Factors participating in degranulation of mast cells, DNAs encoding the same, method of screening of these factors and the inhibitors (2006-09-19),

5. 7084176 - N-arylphenylacetamide derivatives and medicinal compositions containing the same (2006-08-01),

6. 7067491 - Heterocyclic compounds having elastase-inhibiting activity and intermediates thereof (2006-06-27),

7. 6962921 - Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient (2005-11-08),

8. 6900333 - Process for the preparation of 1, 2-dichlorethane free crystals of zonisamide (2005-05-31),

9. 6852744 - Pyrrolidine derivatives and their use as chymase inhibitor (2005-02-08),

10. 6835714 - Heterocyclic compounds, intermediates thereof and elastase inhibitors (2004-12-28),

11. 6765095 - 2,3-disubstituted pyridine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor (2004-07-20),

12. 6743803 - Medicines for the prevention and treatment of neurodegenerative diseases (2004-06-01),

13. 6696468 - (S)-4-AMINO-5-CHLORO-2-METHOXY-N-[1-[1-(2-TETRAHYDROFURYL-CARBONYL)-4-PIPERIDINYLMETHYL]-4-PIPERIDINYL]BENZAMIDE, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND INTERMEDIATE THEREFOR (2004-02-24),

14. 6683186 - 2,3-Disubstituted pyridine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor (2004-01-27),

15. 6646150 - Processes for producing (aminomethyl)trifluorocarbinol derivatives (2003-11-11),

Dainippon Pharmaceutical Company, Limited is a global pharmaceutical company based in Japan. They are committed to the research, development, and manufacturing of innovative pharmaceutical products. With a strong focus on bringing hope to patients and improving their quality of life, Dainippon Pharmaceutical Company strives to contribute to society by providing effective and safe medical solutions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

129 Patents

#90 in Osaka

#929 in Japan

#6,055 in the World

Dainippon Pharmaceutical Company, Limited

Forward Citations = 1,445

225 inventors:

Hitoshi Uno (20 out of 20 patents)

Jun-ichi Matsumoto (15 out of 15 patents)

Shinichi Nakamura (13 out of 13 patents)

4. Kiyoshi Furukawa (13 out of 13 patents)

5. Hideo Nakamura (11 out of 11 patents)

Please report any incorrect information to support@idiyas.com

Loading…